Related Experiment Video

Updated: Apr 9, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

1.4K

Optimizing Obesity Management With GLP-1 Agonist Medication Through Mobile Health Technology, Nutrition Therapy, and

Elizabeth Sharp Edens1, Heather Falise1, Rebecca Smith1

  • 1TouchCare Method, Health Meets Wellness, Bucks Health and Wellness New York New York USA.

Obesity Science & Practice
|April 8, 2026
PubMed
Abstract

Insights

The TouchCare Method, combining nutrition and exercise with GLP-1 RAs, aids significant weight loss while preserving muscle mass and improving cardiometabolic health.

Area of Science:

  • Metabolic Health and Endocrinology
  • Obesity and Weight Management
  • Cardiovascular Risk Reduction

Background:

  • Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are effective for obesity treatment but often cause substantial skeletal muscle mass loss.
  • Limited real-world data exists on lifestyle interventions to preserve muscle mass and mitigate cardiometabolic risks during GLP-1 RA therapy.

Purpose of the Study:

  • To evaluate the TouchCare Method, a lifestyle intervention, in conjunction with GLP-1 RAs.
  • To assess the impact of the TouchCare Method on body composition and cardiometabolic risk factors.

Main Methods:

  • Retrospective chart review of 187 patients using the TouchCare Method (nutrition, exercise, self-monitoring) with GLP-1 RAs for at least 12 months.
  • Primary outcomes: ≥10% weight loss, skeletal muscle mass proportion of weight loss, and changes in lipids, HbA1c, and blood pressure.

Main Results:

  • 69.56% of patients achieved clinically significant weight loss (≥10%); skeletal muscle loss was 12.22% ± 8.73% of total weight loss.
  • Significant improvements observed in glycemic control (74.7% of prediabetics reached euglycemia), blood pressure, and lipid profiles (Total-C, LDL-C, ApoB) (p < 0.001).

Conclusions:

  • The TouchCare Method, a structured lifestyle intervention, may enhance GLP-1 RA efficacy.
  • This approach supports significant weight loss, preserves skeletal muscle mass, and improves cardiometabolic risk factors.
Keywords:
GLP‐1 agonist medicationsTouchCare methodbody compositionchronic disease managementmobile health technologynutrition interventionsobesity managementreal world evidenceskeletal muscle massweight loss

More Related Videos

An Acupoint Catgut-embedding Therapy for Treating Obesity04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

1.9K
A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats06:28

A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats

Published on: April 28, 2023

1.5K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
399
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
345
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.6K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
293